GRADE患者住院与随机降糖治疗的关系

IF 16.6
Diabetes care Pub Date : 2025-07-01 DOI:10.2337/dc24-2839
Daniel S Hsia, Naji Younes, Alokananda Ghosh, Erin J Kazemi, Heidi Krause-Steinrauf, John B Buse, Chelsea Baker, Janet Brown-Friday, Elsa Diaz, Jamie Diner, Erik J Groessl, Elizabeth A Legowski, Cary N Mariash, Andrea H Waltje, Deborah J Wexler, Catherine L Martin
{"title":"GRADE患者住院与随机降糖治疗的关系","authors":"Daniel S Hsia, Naji Younes, Alokananda Ghosh, Erin J Kazemi, Heidi Krause-Steinrauf, John B Buse, Chelsea Baker, Janet Brown-Friday, Elsa Diaz, Jamie Diner, Erik J Groessl, Elizabeth A Legowski, Cary N Mariash, Andrea H Waltje, Deborah J Wexler, Catherine L Martin","doi":"10.2337/dc24-2839","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.</p><p><strong>Research design and methods: </strong>Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk.</p><p><strong>Results: </strong>During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%.</p><p><strong>Conclusions: </strong>Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1288-1294"},"PeriodicalIF":16.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178615/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.\",\"authors\":\"Daniel S Hsia, Naji Younes, Alokananda Ghosh, Erin J Kazemi, Heidi Krause-Steinrauf, John B Buse, Chelsea Baker, Janet Brown-Friday, Elsa Diaz, Jamie Diner, Erik J Groessl, Elizabeth A Legowski, Cary N Mariash, Andrea H Waltje, Deborah J Wexler, Catherine L Martin\",\"doi\":\"10.2337/dc24-2839\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.</p><p><strong>Research design and methods: </strong>Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk.</p><p><strong>Results: </strong>During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%.</p><p><strong>Conclusions: </strong>Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants.</p>\",\"PeriodicalId\":93979,\"journal\":{\"name\":\"Diabetes care\",\"volume\":\" \",\"pages\":\"1288-1294\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178615/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/dc24-2839\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/dc24-2839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较糖尿病降糖方法的住院率和危险因素:一项比较疗效研究(GRADE)的参与者服用二甲双胍并随机分配到甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀。研究设计和方法:使用意向治疗(ITT) (N = 5047)和分配治疗(AT) (N = 4830)数据集。评估住院患者与未住院患者之间的基线差异。Kaplan-Meier分析用于确定首次住院时间的发生率,log-rank检验用于确定治疗组差异。时间-事件分析用于检查影响后续住院风险的因素。结果:在GRADE期间,1,636名参与者(32.4%)至少住院一次,751名参与者(14.9%)住院一次以上。住院的参与者年龄较大,西班牙裔的可能性较小,白人的可能性较大,有高血压病史的可能性较大,基线BMI较高。在ITT数据集中,治疗组在首次住院时间的发生率上没有差异(P = 0.148),但在AT数据集中,观察到利拉鲁肽组与格列美脲组的危险率降低(危险比0.78 [95% CI 0.66, 0.92];P = 0.022)。增加后续住院风险的因素包括满足次要结局(HbA1c >7.5%,确认)、每次先前住院和改变指定治疗(风险分别增加29%、41%和56%)。利拉鲁肽组与格列美脲组相比,降低了13%的风险。结论:住院治疗在GRADE患者中很常见,各治疗组的住院率几乎相同。利拉鲁肽组与格列美脲组之间的后续住院风险虽小但显著降低,这可能会影响与GRADE组相似人群的治疗决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.

Objective: To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.

Research design and methods: Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk.

Results: During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%.

Conclusions: Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
29.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信